Overview
Indications
® SAMSCAis indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
Contraindications
When this intervention should not be used
SAMSCA is contraindicated in the following conditions: Warnings and Precautions (5.2) [see] Patients with autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS Unable to sense or respond to thirst Hypovolemic hyponatremia Warnings and Precautions (5.5) [see] Taking strong
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
10 trials linked to this intervention
Recent Trials
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Tolvaptan in Hyponatremic Cancer Patients
Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Tolvaptan (substance)
- SNOMED CT
- 443058000
- UMLS CUI
- C1176308
- RxNorm CUI
- 358257
- Labeler
- Otsuka America Pharmaceutical, Inc.
Clinical Data
This intervention maps to 0 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.